Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TTP 273

Drug Profile

TTP 273

Alternative Names: TTP-273

Latest Information Update: 17 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator vTv Therapeutics
  • Developer vTv Therapeutics LLC
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Preclinical Diabetes mellitus

Most Recent Events

  • 16 Dec 2019 Phase-II for Type 2 diabetes mellitus is ongoing in USA (PO) (vTv Therapeutics pipeline, December 2019)
  • 04 Dec 2019 vTv Therapeutics plans an adaptive phase I trial for Diabetes mellitus (Cystic fibrosis-related) by the year-end of 2020 (vTv Therapeutics pipeline, December 2019)
  • 04 Dec 2019 vTv Therapeutics plans an adaptive phase II trial for Diabetes mellitus (Cystic fibrosis-related) in second quarter of 2021 (vTv Therapeutics pipeline, December 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top